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Introduction: colorectal cancer (CRC) screening
Since it is the third most common cancer developed and 
the fourth cause of cancer related death worldwide, CRC 
still presents a major health problem (1). However, if 
colorectal neoplasia is detected at an early stage, outcomes 
for individuals are much improved (2). Asymptomatic 
population-based screening programmes for colorectal 
neoplasia have been widely introduced since the criteria 
for successful screening are more than met. Early CRC is 
detected and removal of adenomas, which are sometimes 
precursors of CRC, is expedited. In addition to the wide 
beneficial modification to lifestyles that has ensued over 
recent years, screening is considered to be a major cause 
why both the incidence and mortality of CRC is now 
decreasing, at least in well developed countries (3). There 
are many possible approaches to CRC screening (2), but 
faecal immunochemical tests (FITs) for haemoglobin are 
currently considered the non-invasive investigation of 
choice and are recommended in guidelines promulgated in 
very many countries (4).
FITs for haemoglobin 
FITs are available in two formats, qualitative, generally 
based on immunochromatographic test strips or cassettes, 
and quantitative, generally based on immunoturbidimetry, 
often performed on small benchtop closed systems, 
although one manufacturer supplies reagents and calibrators 
that can be used on a range of open clinical chemistry 
analytical systems (5). Qualitative FITs are often used when 
individual opportunistic screening opportunities arise, 
whereas quantitative FITs are widely used in programmatic 
population-based screening. Quantitative FITs have many 
advantages, a major benefit being that examinations on 
faecal samples allow generation of estimates of the faecal 
haemoglobin (f-Hb) concentration (6). The f-Hb cut-off 
to be applied in CRC screening programmes can then be 
selected on, for example, consideration of the available 
colonoscopy resource. Research has explored many basic 
aspects concerning f-Hb and it has been shown that f-Hb 
rises with age and is higher in men than in women (7,8), and 
higher in the more socioeconomically deprived (8,9). It has 
been well documented that higher f-Hb is associated with 
a higher incidence of CRC and advanced adenoma, that is, 
advanced neoplasia (AN), because f-Hb is directly related 
to the severity of colorectal disease (10). Thus, it is hardly 
surprising that, if FITs are used as a simple qualitative 
dichotomous investigation with a single cut-off f-Hb 
applied to all participants, as is done in almost all current 
CRC screening programmes, as the f-Hb cut-off applied is 
increased, positivity rate, AN detection rate and sensitivity 
decrease, while specificity, positive predictive value and 
interval cancer proportion increase.
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f-Hb concentration and risk
Some time ago now, it was shown by Chen et al. that f-Hb at 
first screening predicts subsequent risk of incident colorectal 
neoplasia and it was suggested that, during follow-up, 
risk stratification based on f-Hb could help clinicians, 
with particular attention being paid to those with higher 
initial f-Hb, especially those just under the f-Hb cut-off 
applied (11). This work has been subsequently extended and 
f-Hb has been demonstrated to be an independent predictor 
of the risk of colorectal neoplasia (12). In Scotland, it has 
been documented that f-Hb is related to detection of AN 
in the next screening round and it was clearly stated that 
studies of f-Hb and outcomes over screening rounds might 
provide strategies to direct available colonoscopy towards 
those at highest risk (13). Indeed, over recent time, there 
has been much interest in improved use of the numerical 
data on f-Hb that can be generated from quantitative FITs, 
particularly in personalised risk assessment. It has been 
suggested that a personalised approach to screening could 
enable those at greatest risk to be referred for colonoscopy, 
optimising resource use and ultimately individual outcomes: 
this recent opinion piece detailed some interesting concepts 
and the work supporting this potentially useful risk-
scoring approach to CRC screening (14). In addition, a 
comprehensive systematic review of risk prediction models 
that could be used for personalisation of screening strategies 
has been recently published, although few to date actually 
incorporate f-Hb, probably the most relevant variable in 
assessment of risk (15).
f-Hb concentrations below the programme 
applied cut-off
These concepts have been considerably supported through 
the recent study of Grobbee et al. (16), which investigated 
the association between f-Hb below the cut-off used in the 
screening studies from The Netherlands, namely 10 µg Hb/g 
faeces, and later development of AN. The study investigated 
9561 average-risk subjects (aged 50–74 years) who were 
offered four rounds of FIT-based screening from November 
2006 through December 2014. Data from 7,663 participants 
screened at least once and found to have a result below 
the f-Hb cut-off were followed for a median of 4.7 years. 
After eight years of follow up, participants with baseline 
concentrations of 8–10 μg Hb/g faeces had a more than six-
fold higher cumulative incidence of AN than participants 
with 0 µg Hb/g faeces Multi-variate hazard ratios increased 
from 1.2 for subjects with f-Hb of 0–2 μg Hb/g faeces to 
8.2 for subjects with concentrations of 8–10 μg Hb/g faeces 
and participants with two consecutive f-Hb of 8 µg Hb/g 
faeces had a 14-fold increase in risk of AN compared to 
participants with two consecutive f-Hb of 0 µg Hb/g faeces.
This very impressive work led to the suggestion 
that that application of these findings might be used in 
designing personalised strategies for population-based 
CRC screening and reduce unnecessary repeat tests. The 
results unequivocally support the concept that an individual 
f-Hb below the programme applied cut-off in a first round 
of screening is an independent predictor for the risk of 
incident AN. Furthermore, it was proposed that consecutive 
low f-Hb could be used in determining personalised 
screening strategies. It would be difficult to disagree that 
these findings point to much better ways to use f-Hb than 
the current single f-Hb cut-off applied to all approach.
It was also stated that the results could aid in informing 
patients about the risk of AN after multiple f-Hb below the 
applied cut-off (traditionally reported as negative, normal 
or low-risk), and to alter screening intervals accordingly. 
This opens up some interesting potential approaches for the 
future, but also poses some dilemmas.
Would readily available data such as age and sex, 
which have been shown to affect f-Hb (7,8) be usefully 
incorporated in a risk-based screening algorithm as 
suggested a number of times (14,17) and already shown 
to be potentially useful in use of f-Hb in the assessment 
of patients presenting with symptoms of CRC (18). This 
would be both simple and inexpensive but, as suggested, 
further research is necessary to determine the benefits of 
more complex algorithms incorporating variables other 
than f-Hb (14).
How should the results for individuals be reported? 
Currently, those with f-Hb higher than the applied 
programme cut-off are offered further investigations, 
usually colonoscopy, and those with f-Hb below the 
cut-off are reassured, given health and lifestyle advice, 
and re-invited at the screening interval adopted by the 
programme. Should individual f-Hb be reported to 
screening programme participants? This would certainly 
involve significant improvement to current communication 
strategies, particularly since the concept of risk seems poorly 
understood. Should participants “know their number” and 
decide on further investigation themselves as an informed 
choice?
If an individual had a f-Hb that is considered to be of 
some risk, but does not wish to undergo further invasive, 
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unpleasant and potentially harmful further investigation, 
would modification of lifestyle factors known to affect CRC, 
such as intake of meat, alcohol consumption, exercise taken, 
smoking habits and body mass index, result in reduction of 
f-Hb and, in consequence, risk of future AN?
It was suggested by Grobbee et al. (16) that, over the 
course of multiple screening rounds, serial f-Hb could then 
be of guidance in identifying those at low and high risk of 
AN, and thus form the basis of individualized screening 
strategies. However, as correctly pointed out, at present, 
no literature is available on trends in individuals with 
f-Hb below the applied cut-off over consecutive screening 
rounds. More importantly, the intrinsic biological variation 
of f-Hb in individuals and the variations caused by pre-
examination factors such as sample collection, handling 
and transport, have not yet been investigated with scientific 
rigour. Such knowledge is a necessary pre-requisite to the 
interpretation of numerical results (19).
f-Hb analyses at low concentrations
The study of Grobbee et al. (16) explored f-Hb below 
the cut-off of 10 µg Hb/g faeces and these f-Hb were 
divided into six categories; 0, >0–2, ≥2–4, ≥4–6, ≥6–8 
and ≥8–10 μg Hb/g faeces. Indeed, it now seems very 
common for academic researchers to explore f-Hb in 
integer steps from 0 µg Hb/g faeces upwards and some 
even use significant figures after the decimal point, a less 
than objective way to report data given the many intrinsic 
sources of variation in obtaining an examination result. It 
was stated that the two FIT analytical systems used, the 
OC-Sensor (Eiken Chemical Co. Ltd, Tokyo, Japan) and 
FOB-Gold (Sentifit270, Sentinel SCH. SpA, Milan, Italy) 
perform equally over the relevant concentration range. 
However, as per their previous work, the examination 
performance characteristics are, in the view of this author, 
not documented adequately (20) and the FITTER 
guidelines of the Expert Working Group on FITs for 
Screening, Colorectal Cancer Screening Committee, World 
Endoscopy Organization (21), were not nearly fulfilled. 
Very importantly, it was stated that the “analytical working 
ranges for the OC sensor μ and Sentifit270 were respectively 
1–200 μg Hb/g faeces and 1–170 μg Hb/g faeces”: in fact, 
these are not correct and enquiries by the author of this 
editorial to the respective manufacturers confirmed these to 
be 10–200 μg Hb/g faeces and 3–136 μg Hb/g faeces. Thus, 
it is germane to ask whether it is acceptable for any work on 
f-Hb to use numerical data below the lower f-Hb quoted in 
the Instructions for Use published by the manufacturer of 
the FIT system used.
Proposals to improve application of low f-Hb 
concentrations
It is highly likely that there is wide misunderstanding 
of the metrological aspects of analysis of f-Hb at low 
concentrations and this is understandable given the “Tower 
of Babel” of current terms used for the lowest concentration 
that can be determined. Moreover, there are a number of 
somewhat conflicting guidelines and recommendations 
from professional and governmental bodies, which does not 
aid clarity. However, since f-Hb is best analysed in medical 
laboratories accredited to ISO 15189 (22), it is suggested 
that the recommendations proposed by the Clinical and 
Laboratory Standards Institute (CLSI), supported by 
the International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) (23), should be applied. These 
are very simple to understand and use in practice.
The limit of blank (LoB) is the highest apparent 
measurand concentration expected to be found when 
replicates of a blank sample containing no measurand 
are tested. The limit of detection (LoD) is the lowest 
measurand concentration likely to be reliably distinguished 
from the LoB and at which detection is feasible. The limit 
of quantitation (LoQ) is the lowest concentration at which 
the measurand can not only be reliably detected, but at 
which some pre-defined goals for examination bias and 
imprecision are met. It is vital to note that the LoQ requires 
definition of analytical performance specifications, which 
can be set using a number of strategies as documented 
by the European Federation of Clinical Chemistry 
and Laboratory Medicine (24) but have not yet been 
explored for determinations of f-Hb. Often, the analytical 
performance specification for imprecision adopted for 
determination of LoQ is coefficient of variation (CV) <5% 
and, in view of the currently attained state of the art of 
f-Hb analysis, this might be at least an interim strategy to 
facilitate the very much needed progress. Bias should be 
negligible and this requires fully traceable assignment of 
f-Hb to calibrators.
It may be that there are differences between academic 
research and the routine reporting of valid numerical results 
in laboratory medicine. A proposal documented here for 
the first time is that the LoD could be used in the academic 
research setting in order to obtain data that could impact 
on the future use of f-Hb in real clinical practice, while the 
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LoQ is the lowest f-Hb that can be reported by ISO 15189 
accredited medical laboratories and all data with lower f-Hb 
should be reported as less than the LoQ. This proposal 
requires wide promulgation and discussion and debate, 
perhaps through the Expert Working Group on FITs for 
Screening, Colorectal Cancer Screening Committee, World 
Endoscopy Organization (the academic community) and 
through the very recently set up IFCC Scientific Division 
Working Group on Fecal Immunochemical Testing (WG-
FIT) (the laboratory medicine community). In any case, 
a necessary prerequisite at this time is that all involved in 
generation and application of f-Hb, namely, FIT analytical 
system manufacturers and suppliers, academic researchers, 
research funding bodies, authors and reviewers of papers, 
reviews and material in modern media, journal editors, and 
professionals in laboratory medicine all use one vocabulary 
and approaches, those of the CLSI recommendations (23). 
It is particularly important that manufactures and suppliers 
document the examination performance characteristics 
at low f-Hb and use the recommended methodology to 
provide data on LoB and LoD and also provide high quality 
precision profiles to calculate LoQ, particularly when 
desirable analytical performance specifications have been 
defined more objectively.
Finally, in view of the interest and undoubted value 
of the determination of low f-Hb, particularly since the 
dogma that has existed for decades is that “everyone has 
blood in their faeces”, it may be that development of a f-Hb 
analytical technique with lower LoB, LoD and LoQ than 
currently available methods would open up further potential 
for research, initially, and then application in real clinical 
practice should very low f-Hb examinations prove of value.
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